Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: yesterday, I wrote “bank” profits from highs

November 6, 2020 7:39am

Today, I’m thankful for being early

Pre-open indications: 1 BUY and 5 SELLs

What I provide is an “intelligence daily” to ensure that shareholders are kept apprised based on a 24-hour surveillance of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times

Dow futures are DOWN -0.54% (-153 points), S&P futures are DOWN -0.74% (-26 points) and NASDAQ futures are DOWN -0.99% (-120 points)

U.S. stock futures are down on Friday as results of the presidential election linger;

European markets were down reacting to rising coronavirus cases and new restrictions across the continent while the pan-European Stoxx 600 fluctuated either side of the flatline in early trade;

Asia-Pacific markets were mixed as investors continued to wait for a result from the U.S. election as the MSCI’s broadest index of Asia-Pacific shares outside Japan rose +0.23%.

Data Docket: October jobs report comes on the variability readings for ADP private payrolls and initial jobless claims.

Henry’omics:

“Slippen’ and sliden’” after four positive closes (and highs) as election, economics and coronavirus create significant headwinds …

Investor focus on Friday likely remained on the U.S. election with the spotlight on a few battleground states such as Arizona and Pennsylvania. Based on NBC News’ tally, Democratic nominee Joe Biden has racked up 253 electoral votes, leaving him 17 short of the 270 needed to win the White House. <CNBC>

Thursday night’s post: RegMed Investors’ (RMi) closing bell: “realizing upside only comes from selling the risk. Always good to take earnings off-the-table, not all but, lightens the risk forward. In these volatile markets, I don’t worry about being under-invested but, prepared for the algorithmic rules!”

The Nasdaq closed UP +300.15 points (+2.59%);
The IBB closed down -0.05% and XBI closed down -0.05%
Sector volume was the usual LOW with 11 of the 20-upside having higher than the 3-month average volume with the increased volume of 8 of 11-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was down -1.99 points or -6.73% at 27.58;
Thursday’s percentage (%) of the 20-upside were +0.20% (FATE) to +9.88% (CLLS) while the 11-downside ranges from -0.26% (QURE) to -16.60% (BLUE);

Q4’s: November, so far: 4 positive closes

Q4’s October: 1 neutral, 11 positive and 10 negative closes
Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed down -$0.10 to $1.37 after Wednesday’s flat at $1.47, Tuesday’s +$0.09 to $1.47 with 450 shares traded after Monday’s flat at $1.38 with 102 shares traded and last Friday’s +$0.02 to $1.38 with 523 shares traded).

Question#1: WHY, NO audit committee board members, financial officers but, they do have a rented “CFO” to prepare the quarterly that current officers don’t want to sign – again, wonder WHY?

BUY:

bluebird bio (BLUE) closed down -$9.72 to $48.83 after Wednesday’s +$4.00 and has a POSITIVE +$0.57 or +1.17% aftermarket indication following earnings release;

Maintaining SELL into strength:

CRISPR Therapeutics (CRSP) closed up +$7.83 to $103.34 after Wednesday’s +$8.69 with a NEGATIVE -$0.27 or -0.26% aftermarket indication;

Mesoblast (MESO) closed up +$0.47 to $11.89 after Wednesday’s $11.42, Tuesday’s $11.26, Monday’s $10.85 and last Friday’s $10.70 with a NEGATIVE -$0.09 or -0.76% aftermarket indication;

Editas Medicine (EDIT) closed up +$1.10 to $31.55 after Wednesday’s +$2.14 and has a POSITIVE +$0.45 or +1.43% aftermarket indication;

SELL:

Ionis Pharmaceuticals (IONS) closed up +$1.11 to $48.73 after Wednesday’s $47.61, Tuesday’s $47.00, Monday’s $46.77 and last Friday’s $46.95 and has a NEGATIVE -$0.41 or -0.84% aftermarket indication

The BOTTOM LINE: Reiterating, “I am troubled by this market; the equity balloon is stretched …today as was yesterday is STILL a wait and see opportunity and the Nasdaq continues to boom.”

A quote from another, ““The race is closer than the market thought,” said Patrick Bennett, a strategist at Canadian Imperial Bank of Commerce. “Reflation is one thing, but a close result - and we are far from the end - is a market negative.”

Now we enter the big upswing in sector earnings’ LPS (loss-per-share) releases with the next month likely to remain volatile and uncertain.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.